ARNI vs ACE inhibitor for children with dilated cardiomyopathy
Part of Heart & circulation clinical trials.
This trial compares a newer heart failure medicine (ARNI) to an older one (ACE inhibitor) in children with a condition called dilated cardiomyopathy, where the heart is enlarged and weak. The goal is to see which medicine works better to help the heart pump more strongly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 1 month and 18 years old.
- Diagnosed with dilated cardiomyopathy (enlarged and weak heart muscle) confirmed by heart ultrasound.
- The heart's main pumping chamber is significantly enlarged.
- Heart function is below normal (ejection fraction less than 45% and shortening fraction less than 25%).
- Your child has been stable for at least 2 weeks before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a heart medicine called ARNI (sacubitril-valsartan) is safe and works well for people who have a durable LVAD and moderate-to-severe heart pumping weakness. It may help improve symptoms and outcomes, while carefully checking side effects in this higher-risk group.
This trial tests if a heart failure drug called ARNI can help people with advanced lung cancer who also have high blood pressure. It aims to see if the drug improves outcomes.
This trial tests a combination of three heart failure drugs (ARNI, SGLT2i, MRA) to see if they improve symptoms and outcomes in people with a type of heart failure where the heart pumps normally but doesn't relax properly (HFpEF).
This trial tests if a specific heart failure pill, started before hospital care, helps improve short-term outcomes in people with weak heart muscles. It is for patients with a low pumping ability of the heart.
This trial tests if a combination medication (sacubitril/valsartan) can improve the heart's ability to relax and fill properly in people with heart failure and a very weak heart pump (ejection fraction less than 35%). It's for patients who are already on standard heart failure medicines.
This study tests whether a medication called sildenafil can help improve heart pumping in children diagnosed with primary dilated cardiomyopathy (a condition where the heart chamber becomes enlarged and weak). Children already on heart failure medications would receive sildenafil to see if it strengthens their heart function.
Hear when a new ARNI trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.